ST. LOUIS — Drug maker Fleming Pharmaceuticals is increasing production of a drug for preventing thyroid cancer in response to the nuclear crisis in Japan.
The drug, ThyroShield (potassium iodide), is designed for use in nuclear emergencies and works by saturating the thyroid gland so that it can’t absorb radioactive iodine.